Yujiro S. Hata

Co-Founder & Chief Executive Officer at IDEAYA Biosciences, Inc.

Yujiro S. Hata

Yujiro S. Hata

Co-Founder & Chief Executive Officer at IDEAYA Biosciences, Inc.

Overview

Career Highlights

Rapt Therapeutics, Inc.
Flexus Biosciences, Inc.
IDEAYA Biosciences, Inc.

RelSci Relationships

801

Number of Boards

5

Birthday

1974

Age

47

Relationships

View Relationship Details

RelSci Relationships are individuals Yujiro S. Hata likely has professional access to. A relationship does not necessarily indicate a personal connection.

Terry Rosen

Chairman & Chief Executive Officer at Arcus Biosciences, Inc.

Relationship likelihood: Strong

Tim Shannon

General Partner at Canaan Management, Inc.

Relationship likelihood: Strong

Jeffrey Stein

President & Chief Executive Officer at Cidara Therapeutics, Inc.

Relationship likelihood: Strong

John Diekman

Founder & Managing Partner at Wildcat Discovery Technologies, Inc.

Relationship likelihood: Strong

Bassil I. Dahiyat

Founder, President & Chief Executive Officer at Xencor, Inc.

Relationship likelihood: Strong

Paul A. Stone

Chief Financial Officer & Executive Vice President at IDEAYA Biosciences, Inc.

Relationship likelihood: Strong

Richard A. Lerner

Co-Founder at Zebra Biologics, Inc.

Relationship likelihood: Strong

Nisha Marathe

Investment Director at Roche Ventures

Relationship likelihood: Strong

Jason S. Throne

Senior Vice President & General Counsel at IDEAYA Biosciences, Inc.

Relationship likelihood: Strong

Jeffrey Hager

Director of Biology at Aragon Pharmaceuticals, Inc.

Relationship likelihood: Strong

Reveal deeper insights into your organization's relationships
with RelSci Contact Aggregator.

Empower Your Business Applications with Industry-Leading
Relationship Data from the RelSci API.

Get Contact Information on the
World's Most Influential Decision Makers.

Discover the Power of Your Network with
RelSci Premium Products.

In The News

PR Newswire

April 19, 2021

IDEAYA Biosciences Announces Agenda for Inaugural Synthetic Lethality Investor Day on Tuesday, April 20, 2021

PR Newswire

April 15, 2021

IDEAYA Announces Dosing of First Patient of MAT2A Inhibitor IDE397 in Phase 1 Clinical Trial Evaluating MTAP-Deletion Solid Tumors; - IDE397 demonstrates significant single-agent anti-tumor activity in a 40-plus MTAP-deletion PDX study, including tumor re

ENP Newswire

March 24, 2021

-IDEAYA Biosciences, Inc. Reports Fourth Quarter 2020 Financial Results and Provides Business Update

PR Newswire

March 23, 2021

IDEAYA Biosciences, Inc. Reports Fourth Quarter 2020 Financial Results and Provides Business Update; - Initiated Phase 1 clinical trial for IDE397, a potential best-in-class MAT2A inhibitor for patients having tumors with MTAP-deletion

PR Newswire

March 23, 2021

IDEAYA Announces Dose Expansion in Phase 1/2 Study of IDE196 and Binimetinib Combination in Metastatic Uveal Melanoma Based on Early Clinical Activity; - Targeting enrollment of approximately 40 patients in the IDE196 and binimetinib clinical combination

Paths to Yujiro S. Hata

Potential Connections via
Relationship Science

You

Yujiro S. Hata

Co-Founder & Chief Executive Officer at IDEAYA Biosciences, Inc.

Education

University of Oxford

Oxford is a collegiate university, consisting of the central University and colleges. The central University is composed of academic departments and research centres, administrative departments, libraries and museums. The 38 colleges are self-governing and financially independent institutions, which are related to the central University in a federal system. There are also six permanent private halls, which were founded by different Christian denominations and which still retain their Christian character.

University of Pennsylvania - The Wharton School

The Wharton School is the business school of the University of Pennsylvania, an Ivy League university in Philadelphia, Pennsylvania. Wharton was the world’s first collegiate business school and the first business school in the United States. It was established in 1881 through a donation of Joseph Wharton.

The Colorado College

Colorado College provide a broad liberal arts education to students. The college was founded in May 6, 1874 and it is headquartered in Colorado Springs, CO

Career History

Co-Founder & Chief Executive Officer

2015 - Current

IDEAYA Biosciences, Inc.

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Chief Operating Officer

2015 - 2015

Rapt Therapeutics, Inc.

Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company. It focuses on discovering, developing and commercializing oral small molecule therapies for patients in oncology and inflammatory diseases.. The company was founded in 2015 and is headquartered in South San Francisco, CA.

Chief Operating Officer

2014 - 2015

Flexus Biosciences, Inc.

Flexus Biosciences, Inc. provides cancer therapeutics through innovative apps. It engages in leveraging unexploited insights in immunology to discover Agents for Reversal of Tumor Immunosuppression. The company was founded by Terry J. Rosen and Juan C. Jaen in 2013 and is headquartered in San Carlos, CA.

Boards & Committees

Director

Current

Experimed Bioscience, Inc.

Experimed Bioscience, Inc. engages in research and development of drugs. The company was founded by Schepartz Alanna and is headquartered in South San Francisco, CA

Transactions

Details Hidden

IDEAYA Biosciences, Inc. raised money in a private placement transaction

Details Hidden

IDEAYA Biosciences, Inc. raised money in a private placement transaction

Investments

Details Hidden

IDEAYA Biosciences, Inc.

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Public Holdings

Restricted data only for RelSci Professional users.

Other Affiliations

Yujiro S. Hata is affiliated with IDEAYA Biosciences, Inc., Rapt Therapeutics, Inc., Flexus Biosciences, Inc., Onyx Pharmaceuticals, Inc., Enanta Pharmaceuticals, Inc., 5AM Venture Management LLC, McKinsey & Co., Inc., Experimed Bioscience, Inc.

Stay informed and up-to-date on your network with RelSci news and business alerting service. Nurture your network and further your business goals with smart intelligence on the people and companies that matter most to you.

Browse in-depth profiles on 12 million influential people and organizations. Find RelSci relationships, employment history, board memberships, donations, awards, and more.

Explore notable alumni from top universities and organizations. Expand your fundraising pool and make warm introductions to potential new business connections.

Harness the power of your relationships with RelSci Pro, the powerful platform for identifying relationship-driven business opportunities and connections that can propel your career forward.

Stay informed and up-to-date on your network with RelSci news and business alerting service. Nurture your network and further your business goals with smart intelligence on the people and companies that matter most to you.

Browse in-depth profiles on 12 million influential people and organizations. Find RelSci relationships, employment history, board memberships, donations, awards, and more.

Explore notable alumni from top universities and organizations. Expand your fundraising pool and make warm introductions to potential new business connections.

Harness the power of your relationships with RelSci Pro, the powerful platform for identifying relationship-driven business opportunities and connections that can propel your career forward.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Yujiro S. Hata. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Yujiro S. Hata's profile does not indicate a business or promotional relationship of any kind between RelSci and Yujiro S. Hata.